SCINAI IMMUNOTHERAPEUTICS LT (SCNI) Fundamental Analysis & Valuation

NASDAQ:SCNI • US09073Q3039

Current stock price

0.67 USD
0 (-0.53%)
Last:

This SCNI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. SCNI Profitability Analysis

1.1 Basic Checks

  • SCNI had positive earnings in the past year.
  • SCNI had a negative operating cash flow in the past year.
  • SCNI had negative earnings in 4 of the past 5 years.
  • SCNI had a negative operating cash flow in each of the past 5 years.
SCNI Yearly Net Income VS EBIT VS OCF VS FCFSCNI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

  • SCNI's Return On Assets of 40.51% is amongst the best of the industry. SCNI outperforms 98.46% of its industry peers.
  • SCNI's Return On Equity of 61.03% is amongst the best of the industry. SCNI outperforms 98.65% of its industry peers.
Industry RankSector Rank
ROA 40.51%
ROE 61.03%
ROIC N/A
ROA(3y)-7.65%
ROA(5y)-13.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SCNI Yearly ROA, ROE, ROICSCNI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300

1.3 Margins

  • SCNI's Profit Margin of 728.88% is amongst the best of the industry. SCNI outperforms 99.23% of its industry peers.
  • SCNI does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 728.88%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCNI Yearly Profit, Operating, Gross MarginsSCNI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. SCNI Health Analysis

2.1 Basic Checks

  • SCNI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SCNI has more shares outstanding
  • SCNI has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for SCNI has been reduced compared to a year ago.
SCNI Yearly Shares OutstandingSCNI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
SCNI Yearly Total Debt VS Total AssetsSCNI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of -16.45, we must say that SCNI is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -16.45, SCNI is not doing good in the industry: 81.12% of the companies in the same industry are doing better.
  • SCNI has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
  • SCNI has a Debt to Equity ratio of 0.04. This is comparable to the rest of the industry: SCNI outperforms 43.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -16.45
ROIC/WACCN/A
WACC6.17%
SCNI Yearly LT Debt VS Equity VS FCFSCNI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

  • SCNI has a Current Ratio of 0.71. This is a bad value and indicates that SCNI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • SCNI's Current ratio of 0.71 is on the low side compared to the rest of the industry. SCNI is outperformed by 88.44% of its industry peers.
  • A Quick Ratio of 0.71 indicates that SCNI may have some problems paying its short term obligations.
  • The Quick ratio of SCNI (0.71) is worse than 88.25% of its industry peers.
Industry RankSector Rank
Current Ratio 0.71
Quick Ratio 0.71
SCNI Yearly Current Assets VS Current LiabilitesSCNI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. SCNI Growth Analysis

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%172.18%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SCNI Yearly Revenue VS EstimatesSCNI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 200K 400K 600K
SCNI Yearly EPS VS EstimatesSCNI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

2

4. SCNI Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 0.24 indicates a rather cheap valuation of SCNI.
  • SCNI's Price/Earnings ratio is rather cheap when compared to the industry. SCNI is cheaper than 100.00% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 25.50, SCNI is valued rather cheaply.
Industry RankSector Rank
PE 0.24
Fwd PE N/A
SCNI Price Earnings VS Forward Price EarningsSCNI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCNI Per share dataSCNI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SCNI Dividend Analysis

5.1 Amount

  • SCNI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SCNI Fundamentals: All Metrics, Ratios and Statistics

SCINAI IMMUNOTHERAPEUTICS LT

NASDAQ:SCNI (3/25/2026, 3:03:20 PM)

0.67

0 (-0.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15
Earnings (Next)N/A
Inst Owners5.72%
Inst Owner Change74.41%
Ins Owners3.49%
Ins Owner Change0%
Market Cap2.32M
Revenue(TTM)658.00K
Net Income(TTM)4.80M
Analysts82.86
Price TargetN/A
Short Float %6042.5%
Short Ratio0.96
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.24
Fwd PE N/A
P/S 3.53
P/FCF N/A
P/OCF N/A
P/B 0.3
P/tB 0.3
EV/EBITDA N/A
EPS(TTM)2.75
EY410.45%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.64
FCFYN/A
OCF(TTM)-1.64
OCFYN/A
SpS0.19
BVpS2.27
TBVpS2.27
PEG (NY)N/A
PEG (5Y)N/A
Graham Number11.84
Profitability
Industry RankSector Rank
ROA 40.51%
ROE 61.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 728.88%
GM N/A
FCFM N/A
ROA(3y)-7.65%
ROA(5y)-13.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.82%
Cap/Sales 2.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.71
Quick Ratio 0.71
Altman-Z -16.45
F-Score5
WACC6.17%
ROIC/WACCN/A
Cap/Depr(3y)91.14%
Cap/Depr(5y)108.59%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%172.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.48%
OCF growth 3YN/A
OCF growth 5YN/A

SCINAI IMMUNOTHERAPEUTICS LT / SCNI Fundamental Analysis FAQ

What is the fundamental rating for SCNI stock?

ChartMill assigns a fundamental rating of 1 / 10 to SCNI.


Can you provide the valuation status for SCINAI IMMUNOTHERAPEUTICS LT?

ChartMill assigns a valuation rating of 2 / 10 to SCINAI IMMUNOTHERAPEUTICS LT (SCNI). This can be considered as Overvalued.


Can you provide the profitability details for SCINAI IMMUNOTHERAPEUTICS LT?

SCINAI IMMUNOTHERAPEUTICS LT (SCNI) has a profitability rating of 3 / 10.


How financially healthy is SCINAI IMMUNOTHERAPEUTICS LT?

The financial health rating of SCINAI IMMUNOTHERAPEUTICS LT (SCNI) is 1 / 10.